BRD7 is a bromodomain-containing chr16 regulator that functions as both a transcriptional coactivator and corepressor, playing critical roles in cell cycle control and tumor suppression. Mechanistically, BRD7 acts as a component of the PBAF chr16 remodeling complex 1 and regulates transcription through histone acetylation and recruitment of cofactors like BRCA1 to target promoters 2. BRD7 promotes p53-mediated transcriptional activation and cell-cycle arrest at the G1/S checkpoint 2, while also negatively regulating the PI3K/AKT/mTOR/STAT3 pathway to suppress PD-L1 expression and enhance CD8+ T cell-mediated immunity 3. BRD7 is downregulated across multiple cancer types including breast, nasopharyngeal, gastric, and prostate cancers, where reduced expression associates with tumor progression 4. Loss of BRD7 promotes metastatic reawakening in breast cancer by suppressing MHC-1 expression and establishing an immunosuppressive microenvironment enriched in pro-tumorigenic neutrophils and exhausted T cells 5. TRIM28-mediated ubiquitination and degradation of BRD7 drives breast cancer progression 6. Additionally, BRD7 mutations emerge as drivers of androgen receptor-targeted therapy resistance in prostate cancer 7. Loss of PBAF function, including BRD7 inactivation, sensitizes tumors to T cell-mediated killing 1, suggesting BRD7 restoration or TRIM28 inhibition as potential immunotherapeutic strategies.